Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 2/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | TOP2A | P11388 | 4/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.30 |
| ▸ | TSHR | P16473 | 2/20 | 0.30 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18083925 | 0.79 | ROCK2 (0.34) | ROCK2ACHECYP3A4CYP2C19MEN1 | |
| SCHEMBL17913009 | 0.77 | DUT (0.35) | DUTROCK2CYP3A4CYP2C19ALDH1A1 | |
| SCHEMBL18048667 | 0.77 | RXFP1 (0.40) | ALDH1A1MEN1KMT2APOLBRXFP1 | |
| SCHEMBL17913007 | 0.77 | DUT (0.35) | DUTROCK2CYP3A4CYP2C19ALDH1A1 | |
| SCHEMBL20924961 | 0.77 | DUT (0.30) | DUT | |
| SCHEMBL18048704 | 0.76 | ROCK2 (0.54) | ROCK2ALDH1A1MEN1KMT2APOLB | |
| SCHEMBL18048783 | 0.69 | MAPT (0.37) | ACHECYP3A4CYP2C19ALDH1A1MEN1 | |
| SCHEMBL22804815 | 0.68 | EPHA2 (0.34) | MEN1KMT2A | |
| SCHEMBL22582347 | 0.68 | DRD2 (0.42) | DUT | |
| SCHEMBL3328338 | 0.66 | GRM2 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3268360-B1 | LACTAMS AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2019-04-24 | — | — | EP | disclosed |
| EP-3268360-B1 | LACTAMS AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2019-04-24 | — | — | EP | disclosed |
| US-10112929-B2 | Lactams as inhibitors of rock | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-10-30 | — | — | US | disclosed |
| US-20180044326-A1 | LACTAMS AS INHIBITORS OF ROCK | BRISTOL-MYERS SQUIBB COMAPANY (US) | 2018-02-15 | — | — | US | disclosed |
| US-20180044326-A1 | LACTAMS AS INHIBITORS OF ROCK | BRISTOL-MYERS SQUIBB COMAPANY (US) | 2018-02-15 | — | — | US | disclosed |
| EP-3268360-A1 | LACTAMS AS INHIBITORS OF ROCK | Bristol-Myers Squibb Company (US) | 2018-01-17 | — | — | EP | disclosed |
| WO-2016144936-A1 | LACTAMS AS INHIBITORS OF ROCK | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180044326-A1 | LACTAMS AS INHIBITORS OF ROCK | MYLK, ROCK1, RHOA | DUT 3861/4885ROCK2 4/4885ACHE 620/4885 |
| US-10112929-B2 | Lactams as inhibitors of rock | MYLK, ROCK1, RHOA | DUT 3859/4885ROCK2 4/4885ACHE 752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.